CHARLOTTE, N.C. (QC Life) – For those battling Alzheimer’s, a new treatment option has become available.
On July 2, the FDA approved Eli Lilly’s Kisunla (donanemab) to help people living with the early symptoms of Alzheimer’s disease. This includes mild cognitive impairment and the mild dementia stage of Alzheimer’s, along with confirmed amyloid plaques.
One of the marks of Alzheimer’s disease is beta-amyloid plaques, and Kisunla is a monoclonal antibody that targets amyloid plaques in the brain.
In a Phase 3 clinical trial of the drug, Kisulna slowed the cognitive and functional decline in people showing early symptoms such as mild cognitive impairment or mild dementia.
The drug is not a cure for Alzheimer’s. However, it slows down the progression and helps give people battling Alzheimer’s more time.
Those who may be eligible for treatment should consult with their doctor to see what is best for them.
Katherine Lambert, the …